Patents by Inventor Stephane Biacchesi

Stephane Biacchesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant human metapneumovirus and its use
    Patent number: 7704491
    Abstract: Recombinant HMPV (rHMPV) and related immunogenic compositions and methods are provided. The rHMPVs, including chimeric and chimeric HMPV vectors viruses, provided according to the current disclosure are infectious and attenuated in permissive mammalian subjects, including humans. The rHMPVs are useful in immunogenic compositions for eliciting an immune response against HPIV, against one or more non-HMPV pathogens, or against a HMPV and a non-HMPV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HMPV genome or antigenome.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: April 27, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Peter L. Collins, Stephane Biacchesi, Ursula Buchholz, Mario H. Skiadopoulos, Brian R. Murphy
  • Use of modified novirhabdoviruses to obtain vaccines
    Publication number: 20060063250
    Abstract: The invention concerns the use of modified novirhabdoviruses wherein the NV protein gene is inactivated to obtain vaccines for use in particular in fish.
    Type: Application
    Filed: May 7, 2003
    Publication date: March 23, 2006
    Applicant: Institut National de la Recherche Agronomique
    Inventors: Michel Bremont, Stephane Biacchesi, Monique Leberre, Maria- Isabel Thoulouze
  • Recombinant human metapneumovirus and its use
    Publication number: 20040241188
    Abstract: Recombinant HMPV (rHMPV) and related immunogenic compositions and methods are provided. The rHMPVs, including chimeric and chimeric HMPV vectors viruses, provided according to the current disclosure are infectious and attenuated in permissive mammalian subjects, including humans. The rHMPVs are useful in immunogenic compositions for eliciting an immune response against HPIV, against one or more non-HMPV pathogens, or against a HMPV and a non-HMPV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HMPV genome of antigenome.
    Type: Application
    Filed: February 27, 2004
    Publication date: December 2, 2004
    Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Peter L. Collins, Stephane Biacchesi, Ursula Buchholz, Mario H. Skiadopoulos, Brian R. Murphy